Literature DB >> 31337508

Protease-activated receptor 4 protects mice from Coxsackievirus B3 and H1N1 influenza A virus infection.

Kohei Tatsumi1, Clare M Schmedes1, E Reaves Houston1, Emily Butler1, Nigel Mackman1, Silvio Antoniak2.   

Abstract

PAR4 is expressed by a variety of cells, including platelets, cardiac, lung and immune cells. We investigated the contribution of PAR4 to viral infections of the heart and lung. Toll-like receptor (TLR) 3-dependent immune responses were analyzed after co-stimulation of PAR4 in murine bone-marrow derived macrophages, embryonic fibroblasts and embryonic cardiomyocytes. In addition, we analyzed Coxsackievirus B3 (CVB3) or H1N1 influenza A virus (H1N1 IAV) infection of PAR4-/- (ΔPAR4) and wild-type (WT) mice. Lastly, we investigated the effect of platelet inhibition on H1N1 IAV infection. In vitro experiments revealed that PAR4 stimulation enhances the expression of TLR3-dependent CXCL10 expression and decreases TLR3-dependent NFκB-mediated proinflammatory gene expression. Furthermore, CVB3-infected ΔPAR4 mice exhibited a decreased anti-viral response and increased viral genomes in the heart leading to more pronounced CVB3 myocarditis compared to WT mice. Similarly, H1N1 IAV-infected ΔPAR4 mice had increased immune cell numbers and inflammatory mediators in the lung, and increased mortality compared with infected WT controls. The study showed that PAR4 protects mice from viral infections of the heart and lung.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Influenza; Innate immune responses; Myocarditis; Protease-activated receptor 4

Mesh:

Substances:

Year:  2019        PMID: 31337508      PMCID: PMC6739161          DOI: 10.1016/j.cellimm.2019.103949

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  62 in total

1.  Inhibition of platelet thromboxane receptor function by a thrombin receptor-targeted pepducin.

Authors:  Jan Julius Stampfuss; Karsten Schrör; Artur-Aron Weber
Journal:  Nat Med       Date:  2003-12       Impact factor: 53.440

2.  Activation of PAR4 induces a distinct actin fiber formation via p38 MAPK in human lung endothelial cells.

Authors:  Masakazu Fujiwara; Enjing Jin; Mohammad Ghazizadeh; Oichi Kawanami
Journal:  J Histochem Cytochem       Date:  2005-05-27       Impact factor: 2.479

3.  Role of thrombin signalling in platelets in haemostasis and thrombosis.

Authors:  G R Sambrano; E J Weiss; Y W Zheng; W Huang; S R Coughlin
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

Review 4.  Thrombin signalling and protease-activated receptors.

Authors:  S R Coughlin
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

5.  Coxsackievirus B3-induced myocarditis: differences in the immune response of C57BL/6 and Balb/c mice.

Authors:  Carola Leipner; Katja Grün; Ilka Schneider; Brigitte Glück; Holger H Sigusch; Axel Stelzner
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 3.402

6.  Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists.

Authors:  J R Hamilton; A G Frauman; T M Cocks
Journal:  Circ Res       Date:  2001-07-06       Impact factor: 17.367

7.  Persistent protease-activated receptor 4 signaling mediates thrombin-induced microglial activation.

Authors:  Zhiming Suo; Min Wu; Bruce A Citron; Chenhua Gao; Barry W Festoff
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

8.  Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo.

Authors:  Morley D Hollenberg; Mahmoud Saifeddine; Sabrina Sandhu; Steeve Houle; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

9.  Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation.

Authors:  Lidija Covic; Meghna Misra; Jehangir Badar; Christopher Singh; Athan Kuliopulos
Journal:  Nat Med       Date:  2002-09-23       Impact factor: 53.440

10.  Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase.

Authors:  Abdelkarim Sabri; Jianfen Guo; Hasnae Elouardighi; Andrew L Darrow; Patricia Andrade-Gordon; Susan F Steinberg
Journal:  J Biol Chem       Date:  2003-01-08       Impact factor: 5.157

View more
  10 in total

1.  Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.

Authors:  Robert H Lee; Tomohiro Kawano; Steven P Grover; Vanthana Bharathi; David Martinez; Dale O Cowley; Nigel Mackman; Wolfgang Bergmeier; Silvio Antoniak
Journal:  J Thromb Haemost       Date:  2021-11-10       Impact factor: 5.824

2.  Protease-activated receptor 4 plays a role in lipopolysaccharide-induced inflammatory mechanisms in murine macrophages.

Authors:  A Barra; K M Freitas; D G Marconato; P Faria-Pinto; M T P Lopes; André Klein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-07       Impact factor: 3.000

Review 3.  Platelets in Viral Infections - Brave Soldiers or Trojan Horses.

Authors:  Waltraud C Schrottmaier; Anna Schmuckenschlager; Anita Pirabe; Alice Assinger
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

4.  PAR1 regulation of CXCL1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus.

Authors:  Silvio Antoniak; Kohei Tatsumi; Clare M Schmedes; Grant J Egnatz; Alyson C Auriemma; Vanthana Bharathi; Tracy Stokol; Melinda A Beck; John H Griffin; Joseph S Palumbo; Nigel Mackman
Journal:  J Thromb Haemost       Date:  2021-02-19       Impact factor: 16.036

5.  Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection.

Authors:  Yogendra Singh; Neeraj Kumar Fuloria; Shivkanya Fuloria; Vetriselvan Subramaniyan; Waleed Hassan Almalki; Gaurav Gupta; Mohammad Arshad Javed Shaikh; Mahaveer Singh; Fahad A Al-Abbasi; Imran Kazmi
Journal:  Drug Dev Res       Date:  2021-09-01       Impact factor: 4.360

6.  Myeloid Protease-Activated Receptor-2 Contributes to Influenza A Virus Pathology in Mice.

Authors:  Randall C Gunther; Vanthana Bharathi; Stephen D Miles; Lauryn R Tumey; Clare M Schmedes; Kohei Tatsumi; Meagan D Bridges; David Martinez; Stephanie A Montgomery; Melinda A Beck; Eric Camerer; Nigel Mackman; Silvio Antoniak
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

7.  Platelet-Mediated NET Release Amplifies Coagulopathy and Drives Lung Pathology During Severe Influenza Infection.

Authors:  Seok-Joo Kim; Agostina Carestia; Braedon McDonald; Amanda Z Zucoloto; Heidi Grosjean; Rachelle P Davis; Madison Turk; Victor Naumenko; Silvio Antoniak; Nigel Mackman; Mohamed Sarjoon Abdul-Cader; Mohamed Faizal Abdul-Careem; Morley D Hollenberg; Craig N Jenne
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

Review 8.  Platelets and viruses.

Authors:  Silvio Antoniak; Nigel Mackman
Journal:  Platelets       Date:  2021-02-22       Impact factor: 3.862

9.  Cell type-specific roles of PAR1 in Coxsackievirus B3 infection.

Authors:  Michael F Bode; Clare M Schmedes; Grant J Egnatz; Vanthana Bharathi; Yohei M Hisada; David Martinez; Tomohiro Kawano; Alice Weithauser; Leah Rosenfeldt; Ursula Rauch; Joseph S Palumbo; Silvio Antoniak; Nigel Mackman
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.996

Review 10.  Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?

Authors:  Simeng Li; Volga Tarlac; Justin R Hamilton
Journal:  Int J Mol Sci       Date:  2019-11-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.